• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was
evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …

always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …

Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …

Importance Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet
therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited …

These Guidelines represent the third time that the ESC and EACTS have brought together
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …